Larimar Therapeutics (LRMR) Shares Outstanding (2013 - 2026)

Larimar Therapeutics (LRMR) has reported Shares Outstanding (Entity) for 14 consecutive years, with $103.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Shares Outstanding (Entity) rose 62.25% year-over-year to $103.9 million; the trailing twelve-month figure through Jun 2026 stood at $103.9 million (up 62.25% YoY), and the FY2025 full-year result was $83.1 million, up 30.2% from the prior year.
• Shares Outstanding (Entity) rose to $103.9 million in Q2 2026 per LRMR's latest filing, from $83.1 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $103.9 million in Q2 2026 and bottomed at $17.7 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $53.7 million across 5 years, with a median of $63.8 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Entity) jumped 144.31% in 2023, then increased 0.35% in 2025.
• Over 5 years, Shares Outstanding (Entity) stood at $25.8 million in 2022, then surged by 70.45% to $43.9 million in 2023, then surged by 45.33% to $63.8 million in 2024, then soared by 30.2% to $83.1 million in 2025, then climbed by 25.02% to $103.9 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $103.9 million, $83.1 million, and $85.6 million for Q2 2026, Q4 2025, and Q3 2025 respectively.